PHARMACOTHERAPY OF OVERACTIVE BLADDER: A 10 YEARS SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/xcgbq616Keywords:
Urinary bladder, overactive, pharmacotherapyAbstract
Background: OAB is a stigmatized condition that significantly affects quality of life. The current first-line pharmacological approach to treating OAB involves various medications, primarily antimuscarinic agents and β3adrenoceptor agonist. This study aims to provide a 10 year systematic review of pharmacological approach in OAB treatment.
Methods: This systematic review adhered to the PRISMA 2020 standards and included full-text English literature published between 2014 and 2024. Exclusion criteria involved editorials, review articles from the same journal, and submissions lacking a DOI. Literature was gathered from online sources such as PubMed and SagePub.
Result: Our search in PubMed yielded 997 articles, while SagePub produced 357 articles. Focusing on the last 10 years (2014-2024), PubMed had 667 articles and SagePub had 160 articles. Ultimately we selected 5 papers that met our criteria, 3 from PubMed and 2 from SagePub.
Conclusion: Due to the the improvements in urgency, frequency, and incontinence as well as fewer treatment-related adverse events, β3-adrenoceptor agonist mirabegron is recommended as the first-line treatment for OAB.
References
Wallace KM, Drake MJ. Overactive bladder. F1000Res. 2015;4:F1000 Faculty Rev-1406.
Allison SJ, Gibson W. Mirabegron, alone and in combination, in the treatment of overactive bladder: real-world evidence and experience. Therapeutic Advances in Urology [Internet]. 2018 Dec 1 [cited 2024 Feb 1];10(12):411–9. Available from: https://doi.org/10.1177/1756287218801282
Hutchinson A, Nesbitt A, Joshi A, Clubb A, Perera M. Overactive bladder syndrome: Management and treatment options. Aust J Gen Pract. 2020 Sep;49(9):593–8.
Kreydin EI, Gomes CM, Cruz F. Current pharmacotherapy of overactive bladder. Int Braz J Urol. 2021;47(6):1091– 107.
Tubaro A, Batista JE, Nitti VW, Herschorn S, Chapple CR, Blauwet MB, et al. Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. Therapeutic Advances in Urology [Internet]. 2017 Jun 1 [cited 2024 Feb 1];9(6):137–54. Available from: https://doi.org/10.1177/1756287217702797
Newgreen D, Bosman B, Hollestein-Havelaar A, Dahler E, Besuyen R, Sawyer W, et al. Solifenacin in Children and Adolescents with Overactive Bladder: Results of a Phase 3 Randomised Clinical Trial. Eur Urol. 2017 Mar;71(3):483–90.
Jamil MN, Irum S, Islam EU. Comparison Of Solifenacin And Mirabegron For The Treatment Of Overactive Bladder. J Ayub Med Coll Abbottabad. 2023;35(2):298–300.
Krhut J, Gärtner M, Petzel M, Sykora R, Nemec D, Tvrdik J, et al. Persistence with first line anticholinergic medication in treatment-naïve overactive bladder patients. Scandinavian Journal of Urology [Internet]. 2014 Feb 1 [cited 2024 Feb 1];48(1):79–83. Available from: https://doi.org/10.3109/21681805.2013.814707
Kraus SR, Li J, Kristy RM, Lockefeer A, Yang H, Zhou M, et al. Evaluating and understanding combination therapy decision drivers for the treatment of overactive bladder in the United States. J Int Med Res [Internet]. 2022 May 1 [cited 2024 Feb 1];50(5):03000605221098176. Available from: https://doi.org/10.1177/03000605221098176
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
